EOLS Evolus, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-13.79
P/S
1.33
EV/EBITDA
-36.78
DCF Value
$8.26
FCF Yield
-10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.5%
Operating Margin
-9.6%
Net Margin
-14.4%
ROE
174.9%
ROA
-19.7%
ROIC
-18.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $73.1M | $-10.7M | $— |
| Q4 null | $90.3M | $130.0K | $— |
| FY null | $297.2M | $-51.6M | $— |
| Q3 null | $69.0M | $-15.7M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$13.00 - $17.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
1.29
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.